Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.065 SEK | +8.67% | +13.30% | -76.64% |
03-28 | Elicera Therapeutics AB Announces Director Changes | CI |
03-06 | Elicera Enters Agreement with Prominent US Cancer Center to Evaluate the Use of ITANK in T-Cell Receptor Therapies | CI |
Business Summary
Number of employees: 2
Managers
Managers | Title | Age | Since |
---|---|---|---|
Magnus Essand
FOU | Founder | 60 | 13-12-31 |
Di Yu
FOU | Founder | 39 | 13-12-31 |
Jamal El-Mosleh
CEO | Chief Executive Officer | 43 | 13-12-31 |
General Counsel | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 63 | 19-12-31 | |
Director/Board Member | 73 | 19-12-31 | |
Chairman | 68 | 19-12-31 | |
Margareth Jorvid
BRD | Director/Board Member | 63 | 19-12-31 |
Magnus Essand
FOU | Founder | 60 | 13-12-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 19,782,000 | 7,601,213 ( 38.42 %) | 0 | 38.42 % |
Company contact information
Elicera Therapeutics AB
World Trade Center Göteborg Mässans gata 10
412 51, Gothenburg
+46 7 03 31 90 51
http://www.elicera.comSector
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-76.64% | 3.21M | |
+32.09% | 694B | |
+29.39% | 593B | |
-1.34% | 371B | |
+20.34% | 331B | |
+7.39% | 290B | |
+14.25% | 239B | |
-3.03% | 209B | |
+10.02% | 209B | |
+8.49% | 169B |
- Stock Market
- Equities
- ELIC Stock
- Company Elicera Therapeutics AB